Swallowable robot-camera could spot stomach cancer early
NCT ID NCT07323186
First seen Jan 10, 2026 · Last updated Jun 20, 2026 · Updated 28 times
Summary
This study tests a new, less invasive way to screen for stomach cancer using a magnetic-guided video capsule that patients swallow. The capsule is steered by a robot and uses AI to check the stomach for suspicious spots. Researchers will compare its accuracy to standard endoscopy in 100 adults aged 50-74 who are already having a colonoscopy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STOMACH CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nantes University Hospital
Nantes, 44000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Magnetically controlled video capsule endoscopy (MC-VCE) device
What this could lead to
If successful, this could offer a less invasive, more accessible screening method for early stomach cancer, potentially improving survival rates.
What could go wrong
This is an early-stage study with only 100 participants, and the capsule may miss lesions that standard endoscopy finds. It is not yet proven for widespread screening.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.